Table 2 Phase II clinical trials of RET tyrosine kinase inhibitors in RET-rearranged lung carcinoma
Study identifier | Drug(dose) | Molecular targets | Primary outcome measure |
|---|---|---|---|
NCT01639508 | cabozantinib (60 mg/day) | MET, VEGFR2, FLT3, c-KIT, AXL and RET | ORR* |
NCT01823068 | vandetanib (300 mg/day) | VEGFR2, EGFR, RET and FGFR-1 | ORR |
NCT01813734 | ponatinib (45 mg/day) | ABL, FLT3, KIT, FGFR, PDGFR, VEGFR2 and RET | ORR |